Scalable, safer, cell-free regenerative medecine.

Evora biosciences develops exosomes-based treatments, the next generation of subcellular therapies.

Evora Biosciences acquires exclusive worldwide rights for digestive fistula treatment from Erganeo

April 8th 2020

Primary target : digestive fistula healing

Digestive fistula can be life-impairing for patients, and are linked to a variety of conditions, such as Crohn’s Disease, or surgical procedures, such as weight-loss procedures like sleeve gastrectomies.

For complex cases, currently available therapeutic options for patients and clinicians are unsatisfactory. Our lead product EVOGEX aims to dramatically improve patient outcomes in several GI-related indications.

EVOGEX stems from world class research in copolymer gels and exosomes, from CNRS and Paris University laboratories.

Exosomes : the next step in regenerative cell therapy

Exosomes are small vesicles produced by cells, from which they carry some very interesting properties. Stem-cells derived exosomes, in particular, are able to virtually replicate the regenerative properties of their parent cells.

Compared to stem cells, exosomes-based treatments offer simpler and more cost-efficient logistics, and greater ease of use for clinicians.

For patients, research has shown that exosomes have a more advantageous risk profile compared to stem cells : no donor rejection, no proliferation or differentiation risks.

The exosomes used in our treatments are produced with high-yield and scale-up compatible technologies. Compared to current-generation cell therapies, this allows for a 10x increase in production throughput in 10x less time.